Abstract
In 2020, the expert panel of the National Asthma and Education Prevention Program recommended the use of single maintenance and reliever therapy consisting of inhaled corticosteroid-formoterol in a single inhaler for patients 4 years and older with moderate to severe persistent asthma not well controlled. Research has suggested single maintenance and reliever therapy is a more effective approach to managing asthma and effectively reduces the number of asthma exacerbations and oral corticosteroid use, providing better control and improved quality of life for children. This article reviews relevant evidence for the new recommendations and how to implement into clinical practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
